BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell Therapeutics and its subsidiary BriaPro presented preclinical findings at SITC 2026 demonstrating positive results for their immunotherapy programs. Bria-OTS+ showed broad immune activation and sustained cancer-cell killing across multiple tumor models, while BP-80 demonstrated good tolerability in primate studies. TILsRx constructs showed enhanced binding affinity for PD-L1, supporting continued development of their immunotherapy pipeline for breast and prostate cancer indications.